CUE · XBRL financial data

Cue Biopharma financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (CUE's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	3,154	14,941	1,245	5,490	9,287	27,466
Research and development	33,546	41,347	38,578	40,802	36,295	37,743
General and administrative	14,651	17,307	16,169	16,680	14,585	16,244
Total operating expenses	48,197	58,653	54,470	57,639	50,787	54,018
Operating income (loss)	(45,043)	(43,712)	(53,225)	(52,149)	(41,500)	(26,552)
Interest expense	—	—	109	130	100	100
Income tax expense (benefit)	206	495	0	—	0	500
Net income (loss)	(44,785)	(44,161)	(53,010)	(50,733)	(40,674)	(26,602)
Earnings per share, basic USD per share	—	(1.41)	(1.49)	(1.11)	(0.72)	(0.28)
Earnings per share, diluted USD per share	—	(1.41)	(1.49)	(1.11)	(0.72)	(0.28)
Weighted average shares, basic thousands of shares	—	31,285	35,649	45,755	56,328	94,732
Weighted average shares, diluted thousands of shares	—	31,285	35,649	45,755	56,328	94,732

Fiscal years (CUE's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	74,866	64,371	51,614	48,514	22,459	27,136
Marketable securities	10,003	0	24,675	0	0	—
Accounts receivable	1,417	3,143	57	1,698	945	5,546
Prepaid and other current assets	1,241	955	841	1,242	805	1,309
Total current assets	87,527	68,468	77,187	51,454	25,138	36,983
Property and equipment, net	2,108	2,112	1,499	795	471	241
Right-of-use asset	6,774	9,810	9,203	6,323	4,370	4,074
Total assets	99,534	83,401	91,283	61,530	32,191	42,212
Accounts payable	2,070	2,591	2,731	3,501	2,823	3,948
Accrued liabilities	2,787	4,620	3,554	4,137	2,908	1,611
Current portion of long-term debt	—	—	2,000	4,000	—	—
Total current liabilities	16,316	12,788	11,549	17,081	13,689	13,494
Long-term debt	—	0	8,035	4,202	0	—
Lease liability, non-current	2,369	5,121	6,018	3,162	1,003	2,286
Total liabilities	20,622	17,909	25,601	24,445	14,692	15,780
Accumulated deficit	(153,285)	(197,446)	(250,457)	(301,190)	(341,864)	(368,466)
Total stockholders' equity	78,911	65,492	65,683	37,085	17,499	26,432
Total liabilities and equity	99,534	83,401	91,283	61,530	32,191	42,212
Common shares outstanding (cover page) thousands of shares	30,457	33,011	43,168	48,643	61,819	97,661

Fiscal years (CUE's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(44,785)	(44,161)	(53,010)	(50,733)	(40,674)	(26,602)
Stock-based compensation	10,481	11,516	9,496	8,180	6,846	4,744
Net cash from operating activities	(32,494)	(38,837)	(41,806)	(39,961)	(36,329)	(21,687)
Purchases of property and equipment	595	913	171	0	66	177
Net cash from investing activities	4,456	9,109	(24,610)	25,002	32	75
Proceeds from issuing common stock	56,682	17,385	22,702	0	10,813	28,289
Share repurchases	271	750	200	0	—	—
Net cash from financing activities	58,614	19,233	53,659	11,860	10,243	26,291
Net change in cash	30,576	(10,495)	(12,757)	(3,099)	(26,054)	4,679

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Cue Biopharma	17,392	7,877	(29,004)*	7.3M	0.6 quarters	Q2 FY26 10-QJun 30, 2026
Fitlife Brands	1,089	not reported	3,635*	9.4M	—	Q2 FY26 10-QJun 30, 2026
Immucell	8,860	7,186	3,019*	9.1M	—	Q2 FY26 10-QJun 30, 2026
Avalo Therapeutics	85,382	not reported	(19,988)*	53.6M	20.0 quarters	Q2 FY26 10-QJun 30, 2026
Precision Biosciences	81,698	0	(15,132)*	27.9M	6.1 quarters	Q3 FY26 10-QSep 30, 2026
iBio	56,395	0*	(6,228)*	64.3M	14.1 quarters	Q4 FY26 10-KJun 30, 2026
Cyanotech	649	6,976	108*	7.4M	—	Q2 FY25 10-QSep 30, 2025
Opus Genetics	88,812	755	(11,950)*	83.2M	7.4 quarters	Q2 FY26 10-QJun 30, 2026
Acumen Pharmaceuticals	53,075	not reported	(26,653)*	72.3M	3.4 quarters	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.